Deep Genomics

Deep Genomics is at the forefront of using artificial intelligence to transform drug development for genetic conditions. The company's core belief is that the future of drug development will rely on AI due to the complexity of biology. Deep Genomics has developed an AI Platform that untangles the intricacies of RNA biology, identifies novel targets, and evaluates thousands of possibilities to determine the best therapeutic candidates. Their goal is to program therapies for any gene and any genetic condition. The company's AI-driven approach has led to significant breakthroughs, including the release of BigRNA, the first Foundation Model for RNA Biology, in 2023. Deep Genomics is currently developing BigRNA+, which will expand their capabilities to pursue more complex genetic diseases and discover new biology. Their AI Platform is designed for data-driven prediction, positive feedback loops, and exponential growth, enabling them to drive an unprecedented number of valuable medicines. The company's focus on RNA as a therapeutic modality is particularly timely, given the recent global success of RNA-based medicines for rare diseases and vaccines. Deep Genomics aims to address the vast potential of genetic conditions, recognizing that everyone will face a genetic condition in their lifetime.